Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tolterodine & Pregabalin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily |
| B | ACTIVE_COMPARATOR | Tolterodine SR 4 mg once daily |
| C | PLACEBO_COMPARATOR | Placebo |
| D | EXPERIMENTAL | Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily |
| E | EXPERIMENTAL | Pregabalin 150 mg twice daily |
| Name | Type | Description |
|---|---|---|
| Tolterodine & Pregabalin | DRUG | Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks |
| Tolterodine | DRUG | Tolterodine SR, Oral, 4 mg, once daily for 4 weeks |
| Placebo | DRUG | Placebo, Oral, twice daily for 4 weeks |
| Pregabalin | DRUG | Pregabalin, Oral, 150 mg twice daily for 4 weeks |
Inclusion Criteria: * Women \> 18 years Old * Diagnosis of OAB (micturition frequency \>/= 8 times per day; urinary urgency \>/= 4 times per week) Exclusion Criteria: * Subjects with symptoms of overactive bladder for less than 6 months prior to randomization. * Significant stress incontinence as...
Tolterodine & Pregabalin is an investigational combination of two small molecules being studied for the treatment of overactive bladder. It is in Phase 2 clinical development and is not approved by the FDA. The combination was evaluated in a completed clinical trial enrolling 188 female participants.
Tolterodine & Pregabalin is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical research on this combination for overactive bladder, with the drug currently in Phase 2 development.
Tolterodine & Pregabalin is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial for the combination has been completed, with no active trials currently listed.
Tolterodine & Pregabalin was studied in a completed Phase 2 trial, NCT00746681, titled 'Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder.' The trial enrolled 188 female participants aged 18 years and older across six European countries.
Tolterodine & Pregabalin is a combination product containing both tolterodine and pregabalin, which are individual drugs. The Phase 2 trial NCT00746681 investigated the combination compared to each component alone and placebo, but the combination is a distinct investigational product.